Background
Methods
Design
Protocol
Literature search
Eligibility criteria
Screening and data extraction process
Critical appraisal
Synthesis
Results
Critical appraisal
Author, year | Pre-print (PP)/ Peer Review (PR) | Source | Average score | Adjust for PP or LE | Total Score (%) | Overall Quality |
---|---|---|---|---|---|---|
Cohort Study Designa | ||||||
Bager, 2021 | PR | Lancet | 9.5 | N/A | 9.5 (86) | High |
Budhiraja, 2021 | PP | MedRxiv | 7.5 | −2 | 5.5 (50) | Medium |
Challen, 2021 | PR | BMJ | 10.5 | N/A | 10.5 (95) | High |
Cusinato, 2021 | PR | Infection | 10.5 | N/A | 10.5 (95) | High |
Dabrera, 2021 | PP | SSRN | 9.5 | −2 | 7.5 (68) | Medium |
Dennis, 2021 | PR | Critical Care Medicine | 9.5 | N/A | 9.5 (86) | High |
Erman, 2021 | PP | MedRxiv | 9.5 | −2 | 7.5 (68) | Medium |
Fisman, 2021 | PP | MedRxiv | 9 | −2 | 7 (64) | Medium |
Frampton, 2021 | PR | Lancet | 10.5 | N/A | 10.5 (95) | High |
Freitas B, 2021 | PP | MedRxiv | 8 | −2 | 6 (55) | Medium |
Grint, 2021 | PR | Clinical Infectious Diseases | 10.5 | N/A | 10.5 (95) | High |
Haas, 2021 | PR | Lancet | 10 | N/A | 10 (91) | High |
Havers, 2021 | PP | MedRxiv | 10.5 | −2 | 8.5 (77) | Medium |
Jassat, 2021 | PR | Lancet Global Health | 10.5 | N/A | 10.5 (95) | High |
Khedar, 2021 | PP | MedRxiv | 9 | −2 | 7 (64) | Medium |
Martin-Blondel, 2021 | PP | SSRN | 8.5 | −2 | 6.5 (59) | Medium |
Maslo, 2021 | PP | MedRxiv | 9.5 | −2 | 7.5 (68) | Medium |
McAllister, 2021 | PP | MedRxiv | 9 | -2 | 7 (64) | Medium |
Nyberg, 2021 | PR | BMJ Open | 11 | N/A | 11 (100) | High |
Ong, 2021 | PR | Clinical Infectious Diseases | 10 | N/A | 10 (91) | High |
Pascall, 2021 | PP | MedRxiv | 10 | -2 | 8 (73) | High |
Patone, 2021 | PR | Lancet | 9.5 | N/A | 9.5 (86) | High |
Peuch, 2021 | PP | Research Square | 10.5 | -2 | 8.5 (77) | Medium |
Stirrup, 2021 | PR | BMJ Open Respiratory Research | 11 | N/A | 11 (100) | High |
Swann, 2021 | PP | MedRxiv | 10 | -2 | 8 (73) | Medium |
Twohig, 2021 | PR | Lancet Infectious Diseases | 9.5 | N/A | 9.5 (86) | High |
Vassallo, 2021 | PR | Journal of Clinical Medicine | 8.5 | N/A | 8.5 (77) | Medium |
Veneti A, 2021 | PR | PLOS One | 9.5 | N/A | 9.5 (86) | High |
Veneti B, 2021 | PP | MedRxiv | 9 | -2 | 7 (88) | High |
Whittaker, 2021 | PR | Journal of Infection | 9 | N/A | 9 (82) | High |
Zavaski, 2021 | PP | Research Square | 9.5 | -2 | 7.5 (68) | Medium |
Cross-sectional Study Designb | ||||||
Adhikari, 2021 | PR | American Journal of Obstetrics & Gynecology | 4 | N/A | 4 (50) | Medium |
Agrawal, 2021 | PR | European Journal of Molecular & Clinical Medicine | 5 | N/A | 5 (63) | Medium |
AlQahtani, 2021 | PP | Research Square | 7 | -2 | 5 (63) | Medium |
Area, 2021 | PR | International Journal of Environmental Research and Public Health | 7 | N/A | 7 (88) | High |
Cetin, 2021 | PR | Acta Microbiologica et Immunologica Hungarica | 5.5 | N/A | 5.5 (69) | Medium |
Courjon, 2021 | PR | Nature | 6 | N/A | 6 (75) | Medium |
de Andrade, 2021 | PP | MedRxiv | 3.5 | -2 | 1.5 (19) | Low |
de Oliveira, 2021 | PP | MedRxiv | 3 | -2 | 1 (13) | Low |
Freitas A, 2021 | PP | SciELO pre-prints | 5.5 | -2 | 3.5 (44) | Low |
Funk, 2021 | PR | Eurosurveillance | 7 | N/A | 7 (88) | High |
Garvey, 2021 | LE | Journal of Infection | 7.5 | −1 | 6.5 (81) | High |
Graham, 2021 | PR | Lancet | 7 | N/A | 7 (88) | High |
Jablonska, 2021 | PP | MedRxiv | 5.5 | −2 | 3.5 (44) | Low |
Loconsole, 2021 | PR | Environmental Research and Public Health | 5 | N/A | 5 (63) | Medium |
Louis, 2021 | LE | Anaesthesia Critical Care & Pain Medicine | 5.5 | −1 | 4.5 (56) | Medium |
Martinez-Garcia, 2021 | PR | Microorganisms | 6 | N/A | 6 (75) | Medium |
Moore, 2021 | PP | MedRxiv | 3 | −2 | 1 (13) | Low |
Nonaka, 2021 | PR | International Journal of Infectious Diseases | 6.5 | N/A | 6.5 (81) | High |
Snell, 2021 | PP | MedRxiv | 6 | −2 | 4 (50) | Medium |
Takemoto, 2021 | PP | MedRxiv | 6 | −2 | 4 (50) | Medium |
Case Control Study Designc | ||||||
Abu-Raddad, 2021 | PR | Clinical Infectious Diseases | 7.5 | N/A | 7.5 (75) | Medium |
Question A: Adjusting capacity planning to accommodate changes in the risk of re-infection and the risk of severe disease (e.g., hospitalization, admission to ICU, and death)
Impact of VOC on hospitalization/severity
VOC | Increased hospitalization/severity due to VOC | No change in hospitalization/severity due to VOC |
---|---|---|
Alpha | • No significant difference was found in hospitalization between Alpha vs. non-Alpha in the crude analysis (RR 0.79, 95% CI 0.72–0.87), but after adjusting for sex, age, region, and comorbidities, Alpha was 1.4 times more likely to be associated with hospitalization than wild type (adjusted RR 1.42; 95% CI 1.25–1.60) (Bager et al., Denmark, Jan-Feb 2021, medium quality )[53] • In wave two (high Alpha prevalence), the number of admissions increased (35.1% vs. 54.8%) from wave one (non-Alpha). Patients with non-Alpha and Alpha were not significantly different in terms of age or ethnicity. Alpha patients were more likely to be female (48.0% vs 41.8%, p = 0.01), less likely to be frail (14.5% vs 22.4%, p = 0.001), and more likely to be obese (30.2% vs 24.8%, p = 0.048) than non-Alpha patients. On admission, patients with Alpha were more likely to be hypoxic, which was the main indicator of severe disease (Snell et al., UK, Mar 2020-Feb 2021, medium quality )[41] • There was a non-significant association between infection with Alpha and hospitalization within 14 days of a positive test (OR 1.39, 95% CI: 0.98-1.98, p = 0.07). In a univariable analysis, Alpha infection and risk of hospitalization within 14 days were not associated (Hazard Ratio (HR) 1.07, 95% CI 0.89-1.29, p = 0.48); however, adjusting for potential confounders (sex, age, ethnicity, residential property classification, and week of specimen date) suggested a higher risk of hospitalization from Alpha (HR: 1.34, 95% CI 1.07-1.66, p = 0.01). (Dabrera et al., UK, Oct-Dec 2020, medium quality)[31] • Individuals with Alpha (SGFT-positive) were more likely to be hospitalized (OR 3.44, 95% CI 1.76-6.75) than non-Alpha (SGFT-negative) cases (Loconsole et al., Italy, Dec 2020-Mar 2021, medium quality )[48] • Alpha was associated with 62% increased risk of hospital admission (aHR: 1.62; 95% CI: 1.48–1.78; P < .0001) compared with wild-type. Among people admitted to a hospital, those with Alpha were younger (median [IQR] age: 57.0 [47.0–68.0] vs 59.0 [48.0–72.0] years) and had fewer comorbidities (≥2 comorbidities: 19.3% vs 25.2%) compared with those with wild-type (Grint et al., England, Nov 2020-Jan 2021, high quality)[58] • Compared to wild-type, the odds of progressing to severe disease were 1.48-fold (95% CI 1.18-1.84) higher for Alpha (Abu-Raddad, Qatar, Jan-May 2021, medium quality)[75] • In the Alpha wave, most hospitalizations were in people over 80, but there was also an increase in hospitalizations in children aged 10 and older (0.21% to 0.35%) compared to previous waves (Area et al., Spain, March-April 2021, high quality)[62] • Alpha increased the chance of hospitalization: 13% of the outpatients had Alpha vs. 33% of inpatients (Cetin et al., Turkey, April 2020-March 2021, medium quality)[46] • The number of COVID-19 admissions was 2.05 times higher in the Alpha wave compared to the pre-Alpha wave. COVID-19 patients admitted during the Alpha wave were more likely to be younger with intermediate levels of frailty (Cusinato et al., UK, January 2020-March 2021, high quality)[55] • In patients hospitalized with COVID-19, Alpha was associated with a 33% higher risk of severe COVID-19 than wild-type (aOR 1.33 95% CI 1.03-1.72) (Martin-Blondel, France, Jan-Feb 2021, medium quality)[34] • Individuals infected with VOC, primarily Alpha, were more likely to require hospitalization (aOR 1.57 [95% CI 1.47-1.69] in Ontario and aOR 1.88 [95% CI 1.74-2.02] in Alberta) than those without VOC (McAlister et al., Canada, March 2020-March 2021, medium quality)[35] • Risk of hospital admission within 14 days after a positive test was higher for patients with Alpha than wild-type (HR 1.52 (95% CI 1.47 to 1.57). The absolute risk of hospital admission after 14 days was 4.7% (95% CI 4.6 to 4.7%) for patients with Alpha and 3.5% (95% CI 3.4 to 3.5%) for those wild-type (Nyberg et al., England, Nov 2020-Jan 2021, high quality)[61] • Alpha was associated with more severe disease than those from other lineages (median cumulative odds ratio: 1.40, 95% CI 1.02-1.93) (Pascall et al., Scotland, Nov 2020-Jan 2021, high quality)[67] • Alpha was associated with a 1·9-fold increased risk of hospitalization compared to non-VOC (aRR 95%CI 1.6-2.3) (Veneti et al., Norway, Dec 2020-Jun 2021, high quality)[71] | • After correcting for mean age, sex, ambient temperature, and humidity, there was no association between Alpha and the number of symptoms reported over a 4-week period after a positive test or the number of hospitalizations (Graham et al., Scotland, Wales and England, Sep-Dec 2020, high quality )[65] • While risk of hospitalization within 14 days of a test and time to hospital admission from symptom onset were similar, Alpha patients were younger, had fewer comorbidities, and more likely to be from an ethnic minority compared to non-Alpha patients (Frampton et al., UK, Nov-Dec 2020, high quality)[57] • Pairing 29 Alpha cases to 58 controls (non-Alpha) on age and gender, there was no significant difference in time from first symptoms to emergency department admission or severity (Courjon et al., France, Dec 2020-Feb 2021, medium quality)[47] • Alpha did not lead to more severe disease in children and young people in the UK, with children admitted during the Alpha wave having lower Paediatric Early Warning Scores (PEWS) at presentation, lower antibiotic use, and less respiratory and cardiovascular support (Swann et al., UK, Jan 2020-Jan 2021, medium quality)[37] • There was no statistically significant difference between time from symptom onset to hospitalization or length of stay between Alpha patients and non-VOC patients (Whittaker et al., Norway, Dec 2020-Apr 2021, high quality)[73] |
Beta | • Compared to Alpha, the odds of progressing to severe disease were 1.24-fold (95% CI 1.11-1.39) higher for Beta (Abu-Raddad, Qatar, Jan-May 2021, medium quality)[75] • Hospital admission rates were significantly higher in the second wave than the first (27.9 vs. 16.1 admissions per 100,000 people). The weekly average growth rate in hospital admissions was 20% in pre-Beta wave and 43% in Beta wave (ratio of growth rate was 1.19, 95% CI 1.18–1.20) (Jassat et al., South Africa, March 2020-March 2021, high quality)[60] • Beta was associated with a 2.4-fold increased risk of hospitalization compared to non-VOC (aRR 95%CI 1.7–3.3) (Veneti et al., Norway, Dec 2020-Jun 2021, high quality)[71] | • Similar amounts of patients were admitted to the hospital in the Beta wave compared to the pre-Beta wave (685 vs. 550), although patients admitted in the Beta wave were older and more likely to have no comorbidities (Maslo et al., South Africa, June-Dec 2020, medium quality)[44] • No differences for patients admitted to hospital with Beta or wild-type in terms of days between onset of symptoms (5 days) (Pascall et al., Scotland, Nov 2020-Jan 2021, high quality)[67] |
Gamma | • There was an increase in proportion of patients with severe COVID-19, from 5% in the first wave to 10% in the second wave (associated with Gamma). There was no difference between sexes, but the proportion of patients with pre-existing conditions among severe cases was higher in the second wave (33%) compared to the first (25%), as well as higher proportion under age 60 (47% vs 39%) (Freitas et al., Brazil, Nov 2020-Feb 2021, medium quality)[28] • The incidence rate of advanced respiratory support (HR 1.78, 95% CI 1.05-3.03, p = 0.03) and invasive respiratory support (HR 2.64, 95% CI 1.34-5.19, p = 0.005) was higher in Gamma patients than non-Gamma patients (Zavascki et al., Brazil, June 2020-May 2021, medium quality)[39] | No data |
Delta | • Among cases admitted to hospitals, mild cases were relatively lower (P < 0.001) and severe cases higher (P < 0.001) in the Delta wave than the first wave (pre-Delta) (Budhiraja et al., India, April 2020-June 2021, medium quality)[29] • Patients with Delta (2.3%) vs. Alpha (2.2%) were more likely to be admitted to hospital within 14 days after a test (aHR] 2.26 [95% CI 1.32–3.89]). Similarly, patients with Delta (5.7%) vs. Alpha (4.2%) were more likely to be admitted to hospital or attend emergency care within 14 days of a test (aHR 1.45 [95% CI 1.08–1.95]) (Twohig et al., UK, March-May 2021, high quality)[70] | • Admission rates were lower in the Delta wave than the pre-Delta wave (23.6% vs. 61.9%) (Khedar et al., India, March 2020-July 2021, medium quality)[43] • No difference was found in the risk of hospitalization among those infected with Delta compared to Alpha (aRR 0.97, 95% CI 0.76–1.23) (Veneti et al., Norway, May-Aug 2021, high quality)[72] |
Combined VOC | • There was a statistically significant increase in the hospitalization rate for regions in the top 10% percentile of reported VOC cases. Regarding time dynamic effects, the hospitalization rate was ~ 38% higher in high VOC regions (9+ VOC cases) compared to their pre-VOC observation (Mitze and Rode, Germany, Jan-Feb 2021, no appraisal)[77] • Significantly higher proportion of VOC cases were admitted to the hospital compared to non-VOC (Alpha: 11.0%, Beta: 19.3%, Gamma: 20.0% vs. non-VOC: 7.5%, p < 0.001). In an adjusted OR in matched multivariable analysis found that VOC cases had higher chance of hospitalization than non-VOC cases (aOR: 1.6-4.2). People aged 20–59 years had 2.3 to 3.0 times greater odds of hospitalization with Alpha compared with non-VOC cases. The highest odds for hospitalization for Beta was 3.5 to 3.6 times higher for age groups 40-79 years compared to non-VOC cases (Funk et al., 7 European countries, Sep 2020-Mar 2021, high quality)[63] • VOC (Alpha, Beta, Gamma) were associated with higher odds of hospitalization (OR 2.25 95% CI 2.10-2.40). These findings were consistent across subgroups (Erman et al., Canada, January-April 2021, medium quality)[32] • Increased rates of hospitalization were seen in VOC infections (all four) relative to non-VOC. Adjusted risk was 59% (95% CI 49-69) higher for hospitalization with VOC (Alpha, Gamma, Beta) than with non-VOC and 120% (95% CI 93-153) higher for hospitalization due to Delta. Increased hospital admission was seen between Delta and other VOC: 55% (95% CI 45-63) (Fisman et al., Canada, Feb-June 2021, medium quality)[33] | No data |
Impact of VOC on admission to ICU
VOC | Increased admission to ICU due to VOC | No change in ICU admission due to VOC |
---|---|---|
Alpha | • In both the adjusted and unadjusted analysis, the primary care group had a higher risk of admission to critical care for Alpha patients compared with the non-Alpha patients (adjusted HR: 2.15; 95% CI 1.75 - 2.65). There was no significant interaction between Alpha and sex, ethnic group, or age group (Patone et al., England, Nov 2020-Jan 2021, high quality)[68] • In the Alpha wave, almost half of total ICU patients were admitted (803 out of the total 1680 patients), suggesting greater ICU admission than pre-VOC (Area et al., Spain, March-April 2021, high quality)[62] • The probability of ICU admission was twice as high among patients with Alpha compared to wild-type (OR 2.11, 95 CI% 1.55 − 2.87) (Martinez-Garcia, Spain, Jan-April 2021, medium quality)[50] • ICU admission was higher with Alpha (6.3%) compared to non-Alpha (3.4%) (Pascall et al., Scotland, Nov 2020-Jan 2021, high quality)[67] • Significantly more hospitalized Alpha patients were transferred to ICU (27.7%) compared to 8.6% of non-Alpha patients (Vassallo et al., France, Oct 2020-Apr 2021, medium quality)[38] • Alpha was associated with a 1.8-fold increased risk of ICU admission compared to non-VOC (aRR 95% CI 1.2-2.8) (Veneti et al., Norway, Dec 2020-Jun 2021, high quality)[71] | • There was no significant difference between those admitted to the ICU before Alpha was dominant (23%) compared to after (26 and 35%), p = 0.374. For ICU patients, neither the severity score at admission (SAPSII) nor the depth of the respiratory distress seemed to increase with Alpha (Courjon et al., France, Dec 2020-Feb 2021, medium quality)[47] • No difference was found for progressing to critical disease between wild-type and Alpha (Abu-Raddad, Qatar, Jan-May 2021, medium quality)[75] • There was no difference in ICU admission between pre-Alpha and Alpha wave (Cusinato et al., UK, January 2020-March 2021, high quality)[55] • No overall increase in ICU admission was associated Alpha (HR 1.01, (95% CI 0.75-1.37, p = 0.94); however, women with Alpha may be at an increased risk of admission to ICU (HR 1.82, 95% CI 1.15-2.90, p = 0.011) (Stirrup et al., UK, Nov 2020-Jan 2021, high quality )[69] • There was no change in the proportion of children and young people admitted to critical care between the pre-Alpha (12.9%) and Alpha wave (12.7%) (Swann et al., UK, Jan 2020-Jan 2021, medium quality)[37] • There was no difference between Alpha patients (16%) and non-VOC patients (18%) admitted to the ICU (Whittaker et al., Norway, Dec 2020-Apr 2021, high quality)[73] |
Beta | • Compared to Alpha, the odds of progressing to critical disease were 1.49-fold (95% CI 1.13-1.97) higher for Beta (Abu-Raddad, Qatar, Jan-May 2021, medium quality)[75] • Beta was associated with a 2.7-fold increased risk of ICU admission compared to non-VOC (aRR 95% CI 1.2-6.5) (Veneti et al., Norway, Dec 2020-Jun 2021, high quality)[71] | • The proportion of patients admitted to the ICU was lower in the Beta wave (35.0%) compared to the pre-Beta wave (48.5%), p < 0.001 (Maslo et al., South Africa, June-Dec 2020, medium quality)[44] • No differences for patients admitted to ICU with Beta (7 days) or wild-type (8 days) in terms of days between onset of symptoms (Pascall et al., Scotland, Nov 2020-Jan 2021, high quality)[67] |
Gamma | • There were more patients admitted to the ICU during the Gamma wave (943) than the pre-Gamma wave (672), particularly among those under 60 years of age and without comorbidities (Nonaka et al., Brazil, May 202-Feb 2021, high quality)[74] | • While there was variation in the age profile of hospitalized patients between Feb 2020-Feb 2021, there was no evidence of an increase in hospitalization in the last period (related to high Gamma) for adults between 18 and 50 years (de Andrade et al., Brazil, Feb 2020-Feb 2021, low quality)[24] • There was no significant difference in the ICU admission risk for maternal patients between 2020 and 2021 (p = 0.769) and there was no difference in length of ICU stay (p = 0.269) (Takemoto et al., Brazil, Mar 2020-Apr 12th, 2021, medium quality)[52] • There was no difference between ICU admission between Gamma and non-Gamma patients (Zavascki et al., Brazil, June 2020-May 2021, medium quality)[39] |
Delta | • Over a quarter of pregnant patients diagnosed during high spread of Delta required admission for severe or critical illness, compared to 5.4% before Delta was prominent (Adhikari et al., United States, May-Sept 2021, medium quality)[45] | • Similar amounts of patients were admitted to the ICU in both waves (34.9% in Wave 1 vs. 33.4% in Wave 2 [Delta]), although more patients required oxygen (74.1% vs 63.4%, p < 0.001) and invasive ventilation during the Delta wave (10.1% in Wave 2 vs. 8.7% in Wave 1, p = 0.002) (Budhiraja et al., India, April 2020-June 2021, medium quality)[29] |
Combined VOC | • There was an estimated increase of 1.29 (95% CI 0.5-2.1, p < 0.05) additional COVID-19 patients in intensive care per 100,000 population, which is a 42% rise in hospitalization in VOC regions compared to pre-VOC regions (3.08 patients in intensive care per 100,000 population) (Mitze and Rode, Germany, Jan-Feb 2021, no appraisal)[77] • VOC cases were more likely to be admitted to the ICU than non-VOC cases (Alpha: 1.4%, p = .002; Beta: 2.3%, p = 0.001; Gamma: 2.1%, p = 0.005 vs. non-VOC: 0.6%). In an unmatched analysis, VOC were 2.2-3.3 times more likely to be admitted to ICU than non-VOC. ICU admission did not differ for Alpha but increased for Beta (adjusted OR 8; 95% CI 3.7–17.3) only for those aged 40–59 years. For individuals aged 40 or older, there was a 2.9 to 13.9 times higher odds of ICU admission with Gamma than non-VOC (Funk et al., 7 Europe, Sep 2020-Mar 2021, high quality)[63] • VOC (Alpha, Beta, Gamma) were associated with higher rates of ICU admission (OR, 3.31; 95% CI 2.84-3.86) compared to previous strains (Erman et al., Canada, January-April 2021, medium quality)[32] • Increased rates of ICU admission were seen in VOC infections (all four) relative to non-VOC. Adjusted risk was 105% (95% CI 82-134) higher for VOC (Alpha, Gamma, Beta) ICU admission than with non-VOC and 287% (95% CI 198-399) higher for ICU admission due to Delta. Increased ICU admission was seen between Delta and other VOC: 101% (95% CI 79-124) (Fisman et al., Canada, Feb-June 2021, medium quality)[33] | • There were no significant differences between VOC and non-VOC on mean LOS (11.51 vs. 9.56 days), mean critical care LOS (15.25 vs. 18.93 days), or proportion of patients admitted to critical care (0.111 vs. 0.19) (Garvey et al., England, Dec 15th-31st, 2020, high quality) [64] |
Impact of VOC on mortality
VOC | Increased mortality due to VOC | Mixed findings in mortality due to VOC | No change in mortality due to VOC |
---|---|---|---|
Alpha | • An increase of 0.1 in the proportion of Alpha in the population was related with a 15.3% increase in the total number of deaths (Jablońska et al., Europe, Jan-Feb 2021, low quality)[27] • The mortality hazard ratio for people with Alpha compared to those with wild-type was 1.64 (95% CI 1.32 to 2.04). In this community-based, relatively low-risk group, there was a 32 to 104% increased risk of death (Challen et al., UK, Oct 2020-Feb 2021, high quality)[54] • The estimated hazard ratio for Alpha was 1.55 (95% CI 1.39– 1.72), indicating that the risk of mortality in the 28 days following a positive test was 55% (95% CI 39– 72%) higher for Alpha than non-Alpha. Correcting for misclassification and missing SGTF status, this increased to 61% (95% CI 42–82%); however, this was not consistent across age groups, with a greater risk in older age groups (70+) (Davies et al., UK, Nov 2020-Feb 2021, no appraisal )[78] • Alpha was associated with 73% increased risk of death within 28 days compared to non-Alpha cases with the hazard ratio at 1.73 (95% CI 1.41–2.13, p < 0.0001) (Grint et al., England, Nov 2020-Jan 2021, high quality)[58] • There is an 18% increase in fatality risk for Alpha compared to non-Alpha with a Case Fatality Rates (CFR) at 1.18 (95% CI 0.40-3.28) (Zhao et al., UK, Sep 2020-Jan 2021, no appraisal)[79] • There was a 33% increase in mortality when considering the effect of Alpha in England (Ackland et al., UK, Sep 21-Nov 5 2020, no appraisal)[80] • The Alpha wave had 39.8% mortality, although the proportion of death in people over 80 was lower: 67.0% compared to 70.9% in across the whole pandemic (Area et al., Spain, March-April 2021, high quality)[62] • There was a marked increase in mortality between pre-Alpha and Alpha wave. The adjusted mortality was 59% (9%5 CI 39–82) higher in high dependency unit and 88% (95% CI 62–118) higher in ICU for the Alpha wave (Dennis et al., UK, March 2020-January 2021, high quality)[56] • VOC-infected patients (primarily Alpha) exhibited higher 30-day risks of death (aOR 1.67, 95% CI 1.13-2.48] in Alberta and aOR 1.52, 95% CI 1.27-1.81] in Ontario) than non-VOC patients (McAlister et al., Canada, March 2020-March 2021, medium quality)[35] • Alpha was associated with a higher risk of death within 28 days than wild-type variants (aHR: 1.59, 95% CI1.44-1.74)) (Nyberg et al., England, Nov 2020-Jan 2021, high quality)[61] • Significantly more hospitalized Alpha patients died (15.4%), compared to 12.9% of non-Alpha patients (Vassallo et al., France, Oct 2020-Apr 2021, medium quality)[38] | • There was an increase in 28-day mortality risk for Alpha compared to non-Alpha patients in both the adjusted and unadjusted model (Adjusted HR: 1.65, 95% CI 1.36-2.01). In the critical care cohort, after adjusting for confounders, critical care mortality did not differ significantly between Alpha and non-VOC Alpha groups (adjusted HR: 0.93, 95% CI 0.76-1.15). Neither cohort had evidence of an interaction between Alpha and ethnic group, age group, or sex (Patone et al., England, Nov 2020-Jan 2021, high quality)[68] • Alpha patients had a slightly higher case-fatality-rate than the non-Alpha patients for younger (e.g. ≤ 70) aged patients, whereas the non-Alpha patients has a higher case-fatality-rate in older ages (Cetin et al., Turkey, April 2020-March 2021, medium quality)[46] • Patients admitted during the Alpha wave had a (crude) mortality rate 25% lower than that of patients admitted during the first wave (IRR 0.75, 95% CI 0.64-0.86). However, in the adjusted analysis, the hazard of death during the Alpha wave was 1.62 times higher (95% CI 1.26-2.08) than during the pre-Alpha wave, considering age, sex, dexamethasone, oxygen requirement, symptoms at admission, and Charlson Comorbidity Index (Cusinato et al., UK, January 2020-March 2021, high quality)[55] • Crude mortality rates were higher during the Alpha wave; however, case fatality rates were lower (Moore et al., Israel, March 2020-Feb 2021, low quality)[26] | • There was no difference in the percentage of patients with and without Alpha who died within 28 days (16% Alpha vs. 17% non-Alpha, p = 0.74). In both the unadjusted and adjusted analysis (controlling for hospital, sex, age, comorbidities, and ethnicity), there was no increased risk of mortality or severe disease with Alpha compared to non-Alpha (Frampton et al., UK, Nov-Dec 2020, high quality)[57] • In a matched cohort analysis, there was no evidence of an association between Alpha and non-Alpha on death within 28 days of COVID-19 positive test (OR 0.90, 95% CI 0.57-1.41, p = 0.64). After adjusting for confounders (sex, age, ethnicity, residential property classification, week of specimen date and testing Pillar), there was no difference in risk of death among Alpha cases compared to non-Alpha (HR 1.06, 95% CI 0.82-1.38, p = 0.65) (Dabrera et al., UK, Oct-Dec 2020, medium quality )[31] • There was no difference found in the death rate between Alpha (0.6%) and non-Alpha individuals (0.9%), p = 0.64 (Loconsole et al., Italy, Dec 2020-Mar 2021, medium quality)[48] • There was no increased risk of 28 day mortality after hospitalization between Alpha and wild-type (Martin-Blondel, France, Jan-Feb 2021, medium quality)[34] • There was no difference in mortality between Alpha patients and wild-type (Martinez-Garcia, Spain, Jan-April 2021, medium quality)[50] • Alpha was not associated with increased mortality at 28 days (OR 1.04, 95% CI: 0.67-1.59) (Pascall et al., Scotland, Nov 2020-Jan 2021, high quality)[67] • Alpha was not associated with increased mortality at 28 days overall (HR 1.01, 95% CI 0.79-1.28, p = 0.94) (Stirrup et al., UK, Nov 2020-Jan 2021, high quality)[69] • There was no statistically significant difference between Alpha patients (9%) and non-VOC patients (6%) in terms of mortality (Whittaker et al., Norway, Dec 2020-Apr 2021, high quality)[73] |
Beta | • Compared to Alpha, the odds of COVID-19 death were 1.57-fold (95% CI 1.03-2.43) higher for Beta (Abu-Raddad, Qatar, Jan-May 2021, medium quality )[75] • Adjusting for weekly COVID-19 hospital admissions, there was a 31% increased risk of in-hospital mortality in the Beta wave (aOR 1.31, 95% CI 1.28–1.35) (Jassat et al., South Africa, March 2020-March 2021, high quality)[60] • Beta was highly associated with 60-day mortality in patients admitted to the ICU compared to both Alpha and wild-type (OR 5.67, 95% CI 1.04–30.81) (Louis et al., France, Feb-March 2021, medium quality )[49] • Patients infected with the Beta variant had a higher 28-day in-hospital mortality (32.5%), compared to patients infected with wild-type (22.2%, p = 0.1). This excess mortality was confirmed after matching for comorbidities and initial severity (30.6% vs. 19.4%, p = 0.04). (Puech et al., France, March 2020-April 2021, medium quality)[36] | • There was no difference in overall mortality between the two waves (36.4% vs. 32.3%), however, ICU mortality was higher in the Beta wave (74.4%) compared to the pre-Beta wave (57.1), p = 0.002 (Maslo et al., South Africa, June-Dec 2020, medium quality)[44] | No data |
Gamma | • There was an 8.2% increase in CFR (15.6% for Gamma from 7.5% wild-type) in maternal deaths out of maternal cases, with the first three months of 2021 accounting for 46.2% of deaths thus far. There was no significant difference in terms of age, type of residence, COVID-19 diagnostic criteria, cardiovascular disease, or diabetes, but the proportion of white women was higher in 2021 (Takemoto et al., Brazil, Mar 2020-Apr 2021, medium quality)[52] • While there were no changes in CFR in children or adolescents, all other groups above 20 years of age had statistically significant increases in CFR when diagnosed in Feb 2021 (Gamma) as opposed to Jan 2021 (non-Gamma). For individuals between 20 and 29 years of age, there was a 3-fold higher risk of death when diagnosed in Feb 2021 compared to Jan 2021 (RR 3.15, 95% CI 1.52-6.53, p < 0.01). This risk of death was also higher in other age groups, although to a lesser extent (de Oliveira et al., Brazil, Jan-Feb 2021, low quality)[25] • Each geographical region of Brazil varied in terms of their mortality over the three periods, with the North region being the hardest hit, experiencing a collapse in the provision of healthcare in the first and last periods (Gamma) with high mortality in all age groups (de Andrade et al., Brazil, Feb 2020-Feb 2021, low quality )[24] • The proportion of women who died from COVID-19 increased from 34% in the first wave (non-VOC) to 47% in the second wave (Gamma). There were no significant differences for mortality in males, but the risk of death for men aged 20-39 was more than double in the second wave than the first wave 2.1 (95% CI 1.6-2.8, p < 0.0001) and was higher in men aged 40-59 years 1.42 (95% CI1.3-1.6, p < 0.0001). Additionally, there was an increase in proportion of deaths for individuals in all age groups (20-59 years) in both sexes (Freitas et al., Brazil, Apr 2020-Jan 2021, low quality)[28] • The CFR was higher across all groups after the emergence of Gamma, with age groups of 20-39 and 40-59 having a higher proportional increase in the second wave than the first wave because of Gamma prevalence. Additionally, people without pre-existing conditions experienced a higher proportional increase in death in the second wave (22%) than the first (13%) (Freitas et al., Brazil, Nov 2020-Feb 2021, medium quality)[30] • 28-day mortality from hospital admission was significantly higher in patients with Gamma than non-Gamma (aHR 3.72; 95% CI 1.19–11.65) (Zavascki et al., Brazil, June 2020-May 2021, medium quality)[39] | No data | No data |
Delta | • Mortality (25%) was higher among people > 60 years compared to other age group (20-40 years (2%), 40-60 years (14%)) during Delta spread (p < .05). Mortality was significantly higher among unvaccinated patients having comorbid conditions than vaccinated patients (p < 0.05) (Agrawal et al., India, Dec 2020-June 2021, medium quality)[40] • Mortality during the Delta wave was nearly 40% higher than in pre-Delta wave (10.5% vs. 7.2%, p < 0.001), across all age groups, with patients under 45 experiencing the greatest increase (Budhiraja et al., India, April 2020-June 2021, medium quality)[29] • In-hospital deaths were significantly higher in the Delta wave (19.3%), compared to pre-Delta (11.5%) (OR 1.84, 95% CI 1.32-2.55), which did not change significantly with adjustment for age, sex, and comorbidities (Khedar et al., India, March 2020-July 2021, medium quality)[43] | No data | No data |
Combined VOC | • VOC (Alpha, Beta, Gamma) were associated with higher odds of mortality for both the general COVID-19 population (OR 1.75, 95% CI 1.47-2.09) and hospitalized cases (OR 1.62; 95% CI 1.23-2.15) (Erman et al., Canada, January-April 2021, medium quality)[32] • Increased rates of mortality were seen in VOC infections (all four) relative to non-VOC. Adjusted risk was 61% (95% CI 40-87) higher for VOC (Alpha, Gamma, Beta) mortality than with non-VOC and 137% (95% CI 50-230) higher for mortality due to Delta than non-VOC. Increased mortality was seen between Delta and other VOC: 59% (95% CI 39-84) (Fisman et al., Canada, Feb-June 2021, medium quality)[33] | No data | • There was no difference in mortality between individuals with Alpha or Beta compared to non-VOC (Garvey et al., England, Dec 15-31, 2021, high quality)[64] • There was no increased risk of death for any of the VOC (Alpha, Beta or Gamma) compared to non-VOC (Funk et al., Europe, Sep 2020-Mar 2021, high quality)[63] |